Work

MRD-Negativity As a Potential Surrogate Endpoint after Frontline DLBCL Therapy: Pooled Analysis of Trials & Implications for Clinical Trial Design

Year: 2022

Type: article

Source: Blood

DOI: 10.1182/blood-2022-167936

Authors: Mark Roschewski, David M. Kurtz, Jason Westin, Ryan C. Lynch, Charles Macaulay, Christian Kuffer, Gregory J. Hogan, Sandra Close, Jacob J. Chabon, Davide Rossi, Maximilian Diehn, Ash A. Alizadeh, Andre Schultz

Institutions: National Cancer Institute, Center for Cancer Research, Stanford Medicine, Stanford University, The University of Texas MD Anderson Cancer Center, Seattle Cancer Care Alliance, Fred Hutch Cancer Center, MorphoSys (Germany), Institute of Oncology Research

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310162918

FWCI: 1.694

Cites:

Cited by: 13

Related to: 10